Critical overview of the main features and techniques used for the evaluation of the clinical applicability of L-asparaginase as a biopharmaceutical to treat blood cancer (2020)
- Authors:
- USP affiliated authors: SILVA, TALES ALEXANDRE DA COSTA E - FCF ; PESSOA JUNIOR, ADALBERTO - FCF ; MONTEIRO, GISELE - FCF
- Unidade: FCF
- DOI: 10.1016/j.blre.2020.100651
- Subjects: BIOFARMACOLOGIA; LEUCEMIA
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Publisher place: Midlothian
- Date published: 2020
- Source:
- Título: Blood Reviews
- ISSN: 0268-960X
- Volume/Número/Paginação/Ano: v. 43, p. 1-17 art. 100651, 2020
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
COSTA-SILVA, Tales Alexandre et al. Critical overview of the main features and techniques used for the evaluation of the clinical applicability of L-asparaginase as a biopharmaceutical to treat blood cancer. Blood Reviews, v. 43, p. 1-17 art. 100651, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.blre.2020.100651. Acesso em: 12 fev. 2026. -
APA
Costa-Silva, T. A., Costa, I. M., Biasoto, H. P., Lima, G. M., Silva, C. M., Pessoa Junior, A., & Monteiro, G. (2020). Critical overview of the main features and techniques used for the evaluation of the clinical applicability of L-asparaginase as a biopharmaceutical to treat blood cancer. Blood Reviews, 43, 1-17 art. 100651. doi:10.1016/j.blre.2020.100651 -
NLM
Costa-Silva TA, Costa IM, Biasoto HP, Lima GM, Silva CM, Pessoa Junior A, Monteiro G. Critical overview of the main features and techniques used for the evaluation of the clinical applicability of L-asparaginase as a biopharmaceutical to treat blood cancer [Internet]. Blood Reviews. 2020 ; 43 1-17 art. 100651.[citado 2026 fev. 12 ] Available from: https://doi.org/10.1016/j.blre.2020.100651 -
Vancouver
Costa-Silva TA, Costa IM, Biasoto HP, Lima GM, Silva CM, Pessoa Junior A, Monteiro G. Critical overview of the main features and techniques used for the evaluation of the clinical applicability of L-asparaginase as a biopharmaceutical to treat blood cancer [Internet]. Blood Reviews. 2020 ; 43 1-17 art. 100651.[citado 2026 fev. 12 ] Available from: https://doi.org/10.1016/j.blre.2020.100651 - Bioprospecting and rational engineering of new L-asparaginase to present a better biopharmaceutical for blood cancer treatment
- Chemogenomic study of gemcitabine using Saccharomyces cerevisiae as model cell—molecular insights about chemoresistance
- Producing L-asparaginase of Erwinia chrysanthemi improved by synthetic evolution of proteins
- Engineered erwinase with possible fewer adverse effects for treatment of acute lymphoblastic leukemia
- Enzima da levedura do pão pode ser alternativa para tratar leucemia infantil
- Heterologous expression and purification of active L-Asparaginase I of Saccharomyces cerevisiae in Escherichia coli host
- Influence and effect of osmolytes in biopharmaceutical formulations
- Double mutant l-asparaginase of Erwinia chrysanthem which may have minor adverse effects
- Characterization of a new microbial ASNase with unique structural characteristics and high citotoxicity over acute lymphoblastic leukemia cells
- Fed-Batch Production of Saccharomyces cerevisiae L-Asparaginase II by Recombinant Pichia pastoris MUTs Strain
Informações sobre o DOI: 10.1016/j.blre.2020.100651 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
